When Fee Cuts Narrow the Path to Mitral Valve Repair

Transcatheter mitral valve repair—often described as transcatheter edge-to-edge repair (TEER) and associated with systems such as MitraClip—can benefit selected people with severe mitral regurgitation. Access begins before the procedure, with specialist consultation, echocardiography, sometimes cardiac CT, and a multidisciplinary assessment of valve anatomy, symptoms, frailty and surgical risk. A narrow evaluation pathway can therefore limit access even when a suitable device is available.

Campaign for Patient Access, launched by the American College of Cardiology, opposed US Medicare physician fee schedule cuts affecting cardiovascular care. Australia does not use Medicare in the same way, and the campaign’s US policy fight cannot be treated as a direct Australian policy issue. Its relevance lies in the mechanism: cuts on access to transcatheter mitral valve repair evaluations can weaken the services that identify appropriate candidates and keep them moving toward treatment.

Why evaluation capacity shapes access

A structural-heart evaluation is more than a paperwork step. It determines whether symptoms arise from severe mitral leakage, whether anatomy suits TEER, and whether surgery, device treatment or medical management is safer. That judgement takes time, imaging expertise and coordination among cardiology, imaging, anaesthesia and cardiac surgery. It also depends on follow-up: a patient may need repeated echocardiography and medication review before a decision is reliable.

When consultation and testing income falls, practices face a choice between absorbing the reduction, reducing complex-clinic time or limiting the services around it. Staffing decisions follow. A nurse specialist may be reduced before a physician is visible on a roster; imaging slots or multidisciplinary meetings may become harder to access. The effect on TEER evaluations can therefore appear as a longer wait rather than an announced closure.

How fee reductions reach the heart team

In the United States, physician fee schedule data can help readers understand the payment framework at issue. Campaign for Patient Access argued that lower Medicare physician payments threatened cardiovascular practices’ ability to sustain evaluation and treatment capacity. The campaign’s concern centred on the cumulative effect of persistent, misaligned reductions across consultations, imaging review, procedures and follow-up.

Reimbursement does not buy a MitraClip directly. It supports the clinicians, facilities and systems around the device: triage, heart-team meetings, bedside echo, operating-room time, recovery care and surveillance. If those components are underfunded, fewer complex cases may be scheduled, thresholds for referral may tighten and patients may be directed toward higher-cost hospital pathways. Conversely, protected funding or cross-subsidy can soften the impact, so cuts do not prove causation on their own.

Australian reimbursement is more fragmented than a single national fee schedule. A cut to one Medicare Benefits Schedule item, for example, may affect a private specialist’s billing but not the public hospital budget that supports a public clinic. Device procurement, insurance products and hospital contracts also shape the final exposure. Any local analysis must therefore trace who receives the payment and which costs sit outside it.

Translating the issue for Australia

Australian patients encounter a mixed public and private system. Public outpatient clinics and elective surgery pathways are funded through state and territory arrangements, while private treatment involves Medicare rebates, private health insurance and sometimes patient contributions. TEER is a high-cost, team-dependent service, so device access is not the same as access to assessment. In Melbourne, Sydney, Brisbane, Perth and Adelaide, major private and public hospitals can offer structural-heart services, but capacity and eligibility differ by network and funding model.

Local customs also influence the journey. Referral is commonly divided between a general practitioner, treating cardiologist and a structural-heart or valve team, with consent discussions that often involve family or carers. Outside metropolitan centres, patients may need to travel to Adelaide, Brisbane, Perth, Melbourne or Sydney for specialist imaging, an echo that can be repeated locally, and multidisciplinary review. The local device market adds another layer through imported products, distributors, hospital purchasing and maintenance training, which means reimbursement must cover more than acquisition cost.

These effects can be compared stage by stage:

Access point	Funding environment	Potential effect of cuts	Australian safeguard
Referral	Prompt specialist review	Delayed or selective triage	Protected referral standards
Imaging	Timely echo and cardiac CT	Fewer slots and more repeat travel	Regional imaging and tele-review
Heart team	Regular multidisciplinary meeting	Less complex case review	Protected team time
Procedure pathway	Established device programme	Reduced selection and scheduling	Ring-fenced device budget
Aftercare	Structured follow-up	Delayed surveillance	Funded remote and in-person review

Where access becomes unequal

The burden is not evenly distributed. People who can travel, take unpaid leave and absorb private gaps may reach a tertiary valve centre despite delays. Those in regional or remote areas, with limited English, disability, unstable housing or few family supports can face a longer chain of referrals and repeat visits. A modest increase in waiting time can therefore become a substantial barrier when each journey costs a day, accommodation and transport.

Clinicians are affected too. A busy private practice may have less capacity for unreimbursed imaging interpretation and complex referrals; a public clinic may carry competing emergency and elective demand. Clinicians may respond by shortening visits, shifting administrative work, declining non-referral enquiries or prioritising patients able to complete the pathway quickly. These responses can increase inequity unless access metrics and support are designed around need rather than ease.

Funding choices that protect the pathway

Cutting a physician fee is rarely the only available budget tool. Health leaders can direct savings toward protected structural-heart clinics, nurse-led follow-up, regional imaging support and coordination rather than removing an entire consultation category. They can also use targeted, time-limited subsidies where a broad reduction would penalise complex care. The aim is to sustain the full pathway, rather than simply preserve the final procedural line item.

Quality safeguards should accompany any funding change. Waiting-time targets can distinguish a short echocardiography queue from the longer wait for a valve-team decision. Audits can record whether eligible patients are being reviewed, whether follow-up is completed and whether outcomes differ by location, insurer or socioeconomic group. Australia’s public hospital system, private insurer contracts and state purchasing arrangements create different levers, so national advocacy should support flexible local responses without ignoring consistent standards.

Actions to preserve timely heart-team access

Patient organisations, cardiology services and policymakers can use a common set of measures:

• Ring-fence multidisciplinary valve-team and advanced imaging capacity when budgets change, rather than treating procedural volume as the only protected service.
• Publish referral criteria, expected timeframes and contact routes for general practitioners so suitable patients are not left in a vague waiting queue.
• Fund regional echo, secure image transfer and tele-heart-team reviews in partnerships with tertiary centres in Melbourne, Sydney, Brisbane, Perth and Adelaide.
• Make device and follow-up costs visible in funding models, including nursing, rehabilitation and remote surveillance.
• Track evaluation-to-decision times, referral losses, repeat tests and patient travel, then publish results by hospital and region.
• Invite patients and carers to describe barriers to access in a safe, consent-based format that protects privacy while giving decision-makers useful evidence.

Individual clinicians can reinforce these safeguards by documenting severity, anatomy, symptoms and the reasons for referral, while patients should ask what stage of the pathway they are waiting for. Advocacy can focus on the full care pathway: a fee cut is consequential when it reduces the assessment capacity needed to make safe, timely decisions.

Keeping evaluation access on the public agenda

Evidence of harm should be gathered carefully. Aggregate data can show changes in referrals, waiting times, public versus private activity and device use after a policy change. Personal accounts add context, particularly when they describe repeated tests, long travel or uncertainty after a fee reduction. Stories should be shared with consent and without identifiable medical details.

Australian patients and families can contact their general practitioner or treating cardiologist to request a structured mitral-regurgitation review, ask how referrals, echocardiography, heart-team assessment and follow-up are funded, and share a consented account of their experience with the campaign or a local patient group. Clinicians and advocates can document local delays and support policies that protect specialist capacity. Together, they can press decision-makers to preserve timely evaluations, because preserving access to transcatheter mitral valve repair begins with ensuring that patients can reach the team that determines whether it is right for them.